Skip to main content
. 2012 Apr 20;74(6):947–958. doi: 10.1111/j.1365-2125.2012.04302.x

Table 1B.

Patient characteristics and type of VTE prophylaxis in patients receiving LMWH or fondaparinux prophylaxis between January 2005 and December 2009. anova group comparisons using covariate analysis for type of thromboprophylaxis, gender and demographic parameters as variables

LMWH n= 1495 Fondaparinux n= 1994
Parameter Gender Mean 95% CI Mean 95% CI P value
History of VTE [%] Male 0.31 0.05, 1.06 0.56 0.19, 1.39 0.751
Female 1.46 0.82, 2.48 1.11 0.65, 1.81
BMI [kg m−2] Male 28.0 27.6, 28.3 29.1 28.7, 29.4 <0.001
Female 27.8 27.5, 28.2 28.9 28.6, 29.2
Platelet count (Gpt l−1) Male 220.1 215.3, 224.8 195.6 191.0, 200.1 <0.001
Female 239.7 235.4, 244.1 215.2 211.4, 219.0
INR Male 1.074 1.07, 1.08 1.117 1.11, 1.12 <0.001
Female 1.068 1.06, 1.08 1.11 1.105, 1.12
aPTT (s) Male 29.0 28.6, 29.4 28.6 28.2, 29.0 0.044
Female 28.9 28.6, 29.3 28.5 28.2, 28.8
Creatinine (µmol l−1) Male 73.22 71.94, 74.51 72.36 71.13, 73.59 0.211
Female 57.99 56.81, 59.17 57.12 56.10, 58.14

LMWH = low molecular weight heparin; aXa = anti-Factor Xa units.